Orthocell has shared that it has completed the first commercial sales of Remplir™ in Canada, marking a key milestone in the Company’s global commercialisation strategy for its flagship nerve repair medical device.
The first sales follow regulatory approval from Health Canada for Remplir and distributor appointments in 2H CY25, which currently provide the majority of national coverage across the Canadian market and position the Company to support surgeon and hospital adoption nationwide.
Orthocell has worked alongside its distributors on initial launch activities, including a KOL-led product roadshow across Canada (Vancouver to Toronto). The program featured Australian orthopaedic surgeon Dr Stuart Kirkham, who presented his clinical experience and use of Orthocell’s Remplir collagen nerve repair device to plastic and orthopaedic peripheral nerve surgeons. This activity supported product education and early engagement, contributing to the first commercial sales.
Following the Canadian launch, Orthocell will continue to work closely with its distributor network to onboard surgeons and establish active accounts, supported by the Company’s existing US-based marketing and medical education teams. This coordinated approach provides clinical engagement, training and operational efficiencies across the U.S. and Canada.
Orthocell Managing Director Paul Anderson said: “We are delighted to announce the first commercial sales of Remplir in Canada, a key milestone following Health Canada approval and the roll out of our distributor-led model, which provides coverage across the majority of this ~US$75 million market.
This milestone represents an important early step in our Canadian commercialisation strategy and reinforces the strength of our execution. We expect increasing surgeon engagement to support continued adoption and further revenue growth.”